A testbench of arbitrary accuracy for electromagnetic simulations

Several electromagnetic problems for verification purposes in computational electromagnetics are introduced. Details about the formulation of a generalized eigenvalue problem for non‐lossy and lossy materials are provided to obtain a fast and ready‐to‐use way of verification. Codes written using the symbolic toolbox from MATLAB are detailed to obtain an arbitrary accuracy for the proposed problems. Finally, numerical results in a finite element method code are presented together with the analytical values to show the accuracy of the code proposed

Experimental insight into the domain decomposition method for a finite element method code

The use of Domain Decomposition Methods (DDM) for a Finite Element Method (FEM) framework was a hot topic in the past decade, leading to very powerful results in terms of scalability and widening the problems that could be full-wave simulated with the FEM, [1–3]. However, despite the promising results shown in these references, it seems not to be a widespread use of the DDM in commercial FEM softwares or publications, whereas the common research topics (adaptivity, higher-order basis functions, different element shapes) in FEM have not been explored together with DDM. In this communication, we share experimental details with different non-overlapping DDM within FEM. We explore the use of different finite element shapes with up to fourth-order basis functions. We propose a propagation problem through a rectangular waveguide as a benchmark, and we show the different implementation choices available and their impact in the performance of the code

Strategies to parallelize a finite element mesh truncation technique on multi-core and many-core architectures

Achieving maximum parallel performance on multi-core CPUs and many-core GPUs is a challenging task depending on multiple factors. These include, for example, the number and granularity of the computations or the use of the memories of the devices. In this paper, we assess those factors by evaluating and comparing different parallelizations of the same problem on a multiprocessor containing a CPU with 40 cores and four P100 GPUs with Pascal architecture. We use, as study case, the convolutional operation behind a non-standard finite element mesh truncation technique in the context of open region electromagnetic wave propagation problems. A total of six parallel algorithms implemented using OpenMP and CUDA have been used to carry out the comparison by leveraging the same levels of parallelism on both types of platforms. Three of the algorithms are presented for the first time in this paper, including a multi-GPU method, and two others are improved versions of algorithms previously developed by some of the authors. This paper presents a thorough experimental evaluation of the parallel algorithms on a radar cross-sectional prediction problem. Results show that performance obtained on the GPU clearly overcomes those obtained in the CPU, much more so if we use multiple GPUs to distribute both data and computations. Accelerations close to 30 have been obtained on the CPU, while with the multi-GPU version accelerations larger than 250 have been achieved.Funding for open access charge: CRUE-Universitat Jaume

On the use of many-core machines for the acceleration of a mesh truncation technique for FEM

Finite element method (FEM) has been used for years for radiation problems in the field of electromagnetism. To tackle problems of this kind, mesh truncation techniques are required, which may lead to the use of high computational resources. In fact, electrically large radiation problems can only be tackled using massively parallel computational resources. Different types of multi-core machines are commonly employed in diverse fields of science for accelerating a number of applications. However, properly managing their computational resources becomes a very challenging task. On the one hand, we present a hybrid message passing interface + OpenMP-based acceleration of a mesh truncation technique included in a FEM code for electromagnetism in a high-performance computing cluster equipped with 140 compute nodes. Results show that we obtain about 85% of the theoretical maximum speedup of the machine. On the other hand, a graphics processing unit has been used to accelerate one of the parts that presents high fine-grain parallelism.This work has been fnancially supported by TEC2016-80386-P, TIN2017-82972-R, CAM S2013/ICE-3004 projects and “Ayudas para contratos predoctorales de Formación del Profesorado Universitario FPU”

3D magnetotelluric modeling using high-order tetrahedral Nédélec elements on massively parallel computing platforms

We present a routine for 3D magnetotelluric (MT) modeling based upon high-order edge finite element method (HEFEM), tailored and unstructured tetrahedral meshes, and high-performance computing (HPC). This implementation extends the PETGEM modeller capabilities, initially developed for active-source electromagnetic methods in frequency-domain. We assess the accuracy, robustness, and performance of the code using a set of reference models developed by the MT community in well-known reported workshops. The scale and geological properties of these 3D MT setups are challenging, making them ideal for addressing a rigorous validation. Our numerical assessment proves that this new algorithm can produce the expected solutions for arbitrarily 3D MT models. Also, our extensive experimental results reveal four main insights: (1) high-order discretizations in conjunction with tailored meshes can offer excellent accuracy; (2) a rigorous mesh design based on the skin-depth principle can be beneficial for the solution of the 3D MT problem in terms of numerical accuracy and run-time; (3) high-order polynomial basis functions achieve better speed-up and parallel efficiency ratios than low-order polynomial basis functions on cutting-edge HPC platforms; (4) a triple helix approach based on HEFEM, tailored meshes, and HPC can be extremely competitive for the solution of realistic and complex 3D MT models and geophysical electromagnetics in general

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention